BRIEF—Evotec and Indivumed begin new project

Germany’s Evotec and Indivumed have agreed a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer (NSCLC).

Evotec will use its bioinformatics analysis platform, PanHunter, and its small molecule and antibody discovery platforms, together with Indivumed’s analytics and AI capabilities.

Indivumed chief executive Hartmut Juhl said: "The fast and successful development of our previous joint colorectal cancer programme has led to this new agreement, less than twelve months after the first one.”

No financial details of the agreement were disclosed.